Oath Research product quality: what 199 tested batches show

The portfolio reading

The single most useful number on the product-quality side is the portfolio average: 99.60% purity across the visible 199-batch archive. Numbers in the high 99s are not the universal floor in commercial research peptides — the broader category often sits in the 95-98% band — and a portfolio average above 99% is consistent with the cadence claim that the RealPeptidesScores audit summarizes as "per-batch, portal-verifiable, and four times the cadence of anyone else." Public record verified

The portfolio reading is also worth taking apart by compound. Averages can hide variance, and a 99.60% mean across 199 batches could in principle conceal a few low outliers offset by a few near-perfect peaks. The per-compound breakdown below — drawn from the May 2026 snapshot of the COA archive — shows that the high results are not concentrated on one favorable compound. The pattern holds across mitochondrial peptides, healing peptides, blends, and the GLP-1 line.

Oath Research peptides reviewed: per-compound test results

The following selected examples are drawn directly from the May 2026 COA snapshot. The full catalog is larger; this list reflects the subset captured at scrape time with verified test data.

GLP2-T (Tirzepatide) — 99.93% latest purity, ENDO PASSED, 8 tests on file, latest May 2026. The top of the visible range. Tirzepatide is the GLP-1/GIP dual agonist that anchors the GLP-1 product line; the 99.93% result is independently corroborated by a customer-funded retest at oath.reviews (reviewer Nancy I., 2026-05-23: "Sent my own sample of their tirzepatide for an independent test and it lined up with the posted COA."). Independently corroborated

SS-31 — 99.86% latest purity, ENDO PASSED, 4 tests on file, latest May 2026. A mitochondrial-targeted peptide that demonstrates catalog breadth beyond healing and GLP-1 work. Second-highest visible purity result.

Selank — 99.71% latest purity, ENDO PASSED, 5 tests on file, latest May 2026. A nootropic peptide. Another category — neither healing nor metabolic — confirming the program's coverage across multiple peptide classes.

BPC-157 — 99.66% latest purity, ENDO PASSED, 10 tests on file, latest May 2026. The highest visible test count in the snapshot. Ten independent batches across the pentadecapeptide GEPPPGKPADDAGLV. Independently referenced at oath.reviews (reviewer Jeffrey H., 2026-05-18: "Ordered BPC-157 and the COA QR scanned to a real HPLC report that matched the lot.").

Tesamorelin + Ipamorelin blend — 99.43% latest purity, ENDO PASSED, 6 tests on file, latest May 2026. Specific batches B0526 (2026-05-05) and 66CBF (2026-01-12) are independently visible on the RealPeptidesScores audit page — direct cross-verification possible from a third-party source.

BPC-157 + TB-500 (WOLVERINE blend) — 99.39% latest purity, ENDO PASSED, 8 tests on file, latest May 2026. Blend testing at batch level is not always industry-standard; its presence here is a meaningful signal. Independent corroboration at oath.reviews (reviewer Wesley Y.): "WOLVERINE blend arrived fast, vials filled correctly, COA posted for the lot."

GLP3-R (Retatrutide) — visible in catalog, specific test data not captured in this snapshot. Batch A1226 (2026-04-29) appears on the RealPeptidesScores audit page, so at least one independently audited batch exists; this review does not extrapolate beyond what the public record verifies.

What the per-compound spread tells us

Three observations land from the table above. First, the high-end results (99.93%, 99.86%) and the lower-end blend results (99.43%, 99.39%) sit roughly half a percentage point apart. That is a tight distribution. A vendor reporting an inflated portfolio average would typically show wider variance and more outliers. Second, the blend purities are lower than the monomer purities in a way that is chemically expected — blended formulations carry two peptides through a single endotoxin and purity workup, and the HPLC integration must distinguish between two peptide peaks and any minor impurities. The fact that blend numbers sit near 99.4% rather than dropping below 99% is consistent with a credible workup. Third, every visible endotoxin test passed. The combination — tight purity distribution plus 100% endotoxin pass-rate in the visible sample — is the structural argument for the product-quality pillar. Partial fetch — snippet-verified

What is Oath Research's average purity?

99.60% average purity across the publicly archived 199 tested batches. Per-compound highlights from the May 2026 snapshot include GLP2-T (Tirzepatide) at 99.93%, SS-31 at 99.86%, Selank at 99.71%, BPC-157 at 99.66% across 10 batches, and the Tesamorelin + Ipamorelin blend at 99.43%.

What peptides does Oath Research sell?

The verified catalog includes (selected examples from the May 2026 snapshot) SS-31, BPC-157, Selank, GLP2-T (Tirzepatide), GLP3-R (Retatrutide), and blended formulations including BPC-157 + TB-500 (WOLVERINE blend), Tesamorelin + Ipamorelin, BPC-157 + TB-500 + GHK-Cu, and BPC-157 + TB-500 + GHK-Cu + KPV. The full catalog is larger and is publicly visible on the vendor's catalog page; this is a subset visible at scrape time.

Does Oath Research test blended peptide formulations?

Yes. Blended formulations are tested at the same batch level as monomers — the BPC-157 + TB-500 (WOLVERINE) blend has been verified across 8 batches at 99.39% latest purity with endotoxin passed, and the Tesamorelin + Ipamorelin blend across 6 batches at 99.43%. Specific blend batches (Tesamorelin + Ipamorelin B0526 and 66CBF) are independently visible on the RealPeptidesScores audit page. Blend testing is not always industry-standard, so its consistent presence in the program is a meaningful signal.